Giovannoni G, de Seze J, Kappos L et al. (2017).
An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. EUROPEAN JOURNAL OF NEUROLOGY.
vol. 24,
494-494.

Havrdova E, Arnold DL, Bar-or A et al. (2017).
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. EUROPEAN JOURNAL OF NEUROLOGY.
vol. 24,
497-497.

Baker D, Anandhakrishnan A, Tuite-Dalton KA et al.(2016).
How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. Mult Scler Relat Disord
vol. 10,
127-133.

Giovannoni G, Arnold D, Cohen J et al. (2016).
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment. NEUROLOGY.
vol. 86,

Dua P, Jacobson L, Church A et al. (2014).
Detection of antibodies against the N-methyl-D-aspartate receptor in a sub-group of patients diagnosed with Tourette's syndrome. JOURNAL OF NEUROIMMUNOLOGY.
vol. 275,
98-98.

Cook SD, Dhib-Jalbut S, Dowling P et al.(2012).
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. Int J MS Care
vol. 14,
(3)
105-114.